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Parameter Wild Type Tas1R3 KO p value
Osteoclast
Cortical Osteoclast Number 
(Oc.N/B.Pm)
5.230±1.540 6.219±1.863 0.7035
Cortical Osteoclast Surface (Oc.S/BS) 0.09106±0.026 0.1183±0.040 0.6314
Trabecular Osteoclast Number 
(Oc.N/B.Pm)
7.621±0.9471 8.358±1.009 0.6226




Trabecular Osteoblast Number 
(Ob.N/B.Pm)
20.78±3.288 16.07±2.767 0.3344
Trabecular Osteoblast Surface 
(Ob.S/BS)
14.8±3.523 12.88±2.921 0.6956
Fig. 2: A-B: Quantification of Procollagen Type I N-terminal Propeptide (PINP) (Fig, 2A) and CTx (2B) levels
in serum from twenty-week-old male wild type and Tas1R3 knock-out (KO) mice; data are expressed as
mean±SEM. n≥5 for each group. p=0.7 by unpaired t test.
A B
Fig. 3: A: Histomorphometric analyses of femora from twenty-week-old Tas1R3 mutant and wild type mice.
B: Quantification of fold change in RANKL expression observed in twenty-week-old male mice huerii; data
expressed as mean±SEM. N=5 for each group. C: Quantification of Trap/Acp5 observed in twenty-week-old




• Cortical bone mass is increased in TAS1R3 knock out mice and is associated with decreased 
osteoclast activity with no observed defect in osteoblast parameters.
• RAW264.7 osteoclast precursor cells express Tas1R3 and are responsive to the ligand 
saccharin upon differentiation using RANKL. 
• Future studies will attempt to inhibit TAS1R3 function using gurmarin, a known antagonist, 




Fig. 4: A: RT-PCR expression of Tas1R3 and Tas1R2 in murine primary cells after RANKL
differentiation. Hprt used as loading control. B-E: Differentiation assay using RAW264.7
osteoclast precursor cells treated with RANKL (B, right) for six days compared to control (B,
left). Osteoclast differentiation confirmed by up-regulation of Ctsk mRNA (C) and protein (E)




































































































































Figure 5: Western Blot(A) and densitometry (B-C) for phosphorylated isoforms of ERK1/2
and p70/S6 Kinase in response to activation of TAS1R3 with saccharin. β-actin used as
loading control.
A B C
Current therapies for diseases of low bone mass consist of inhibiting osteoclast activity or increasing the PTH or Wnt signaling
pathways. While largely effective, these approaches have significant drawbacks that limit their use in specific patient
populations and/or negatively impact patient compliance with therapy. Thus, there is a need to identify new therapeutic targets
and, we contend, this requires diversifying our understanding of the mechanisms underlying postnatal bone remodeling by
examining lesser-known signaling pathways. One such pathway is the taste receptor type 1 (TAS1R) family of heterotrimeric G
protein-coupled receptors, which participates in monitoring energy and nutrient status. Simon et al. (2015) reported that global
deletion of TAS1R member 3 (TAS1R3), which is a bi-functional protein that recognizes amino acids or sweet molecules when
dimerized with TAS1R member 1 (TAS1R1) or TAS1R member 2 (TAS1R2), respectively, leads to increased cortical bone
mass. But, the underlying cellular mechanisms leading to this phenotype remain unclear. Here, we independently corroborate
the increased thickness of cortical bone in femurs of 20-week-old male Tas1R3 knockout mice and confirm that Tas1R3 is
expressed in the bone environment. Quantification of serum bone turnover markers indicate that this phenotype is likely due to
uncoupled bone remodeling, with levels of the bone resorption marker CTx being reduced greater than 60% in Tas1R3 mutant
mice; no changes were observed in levels of the bone formation marker PINP. Consistent with this, Tas1R3 and its putative
signaling partner Tas1R2 are expressed in primary osteoclasts and RAW264.7 cells following RANKL-mediated differentiation.
Moreover, the responsiveness of RAW264.7 cells to the TAS1R2:TAS1R3 ligand saccharin, as indicated by phosphorylation of
ERK1/2 and S6 Kinase, is increased in RANKL-treated RAW264.7 cells. These findings suggest that osteoclast function and/or
differentiation may be altered in the absence of Tas1R3 expression. To test this, we quantified bone-specific expression of
Rankl and determined the Rankl:Opg ratio; however, no differences were observed between control and Tas1R3 knockout mice
in these analyses. Studies involving in vitro functional assays is control versus Tas1R3-deficient osteoclasts are currently
underway. Collectively, our findings provide the first demonstration that nutrient monitoring by TAS1R3 is essential for normal
bone resorption in vivo.
Fig. 1: Evaluation of bone mass in Tas1R3 mutant mice. A-B: A, Quantification of average thickness of the cortical bone (cortical
thickness, C.Th) at the femoral mid-diaphysis of twenty-week-old male Tas1R3 knock-out (KO) as compared to wild types; data
are expressed as mean±SEM, n=3 for each genotype and * indicates p<0.05 by unpaired t test. B, Images of mid-diaphyseal
bone for wild type and Tas1R3 KO most representative of the genotype mean in A; scale bar is 200 μm. C: RT-PCR for TAS1R
family members in nine-week-old marrow-free humeral diaphysis from wild type mouse; Hprt serves as loading control. Data are
representative of five marrow-free humerii.
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